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Abstract 
The choice of an appropriate medium for dissolution tests is an essential step during a dosage form 
development. The adequate design of dissolution testing enables forecasting in vivo behavior of drug 
formulation. Biorelevant media were developed for this purpose because dissolution media described in the 
International Pharmacopoeia are not thoroughly suitable. Therefore, we carried out solubility and 
dissolution tests in biorelevant media and we compared the results with data measured in compendial 
dissolution media. A shake-flask method and standard paddle apparatus were used. The concentration was 
measured by a UV-Vis spectrophotometer. An oral solid dosage form with poorly soluble drug candesartan 
cilexetil was tested. Significant differences in the solubility and dissolution profiles of candesartan cilexetil 
were observed. The study offers the overview of compendial and biorelevant media simulating fasted state 
that can be analyzed by a spectrophotometric technique. 
Keywords 




During a drug dosage form development it is essential to investigate factors which influence drug 
absorption, especially after oral administration. The prediction of limiting factors can be facilitated by in 
vitro tests [1]. In vitro dissolution tests should mimic a drug performance in a human proximal 
gastrointestinal tract (GIT). To establish reliable in vitro testing it is important that artificial environments 
simulate physiological conditions as closely as possible. The level of the simulation is dependent on many 
factors related to used equipment and medium. A physiological relevant dissolution medium is great 
contribution to in vitro dissolution tests [2]. 
Dissolution media were initially intended mainly for quality control purposes and water was frequently 
used as the dissolution medium. However, later approach led to the development of new media which 
resemble gastrointestinal fluids. Simulated Gastric Fluid (SGF) and Simulated Intestinal Fluid (SIF) were the 
first proposals [3]. Both artificial fluids are described in the International Pharmacopoeias. These media 
reflect roughly pH conditions and the enzyme activity in the stomach (SGF contains pepsin, pH 1.2) and 
small intestinal (SIF contains pancreatin, pH 6.8). Nevertheless, there are variants without enzymes – SGFsp 
(sine pepsin) and SIFsp (sine pancreatin) [4]. SGF and SIF do not contain any surfactants, although 
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surfactants have been commonly used to improve the solubility of low soluble drugs. Therefore, Dressman 
et al. [5] and Galia et al. [6] proposed addition of synthetic surfactants – Triton X®-100 (SGFTriton) and 
sodium lauryl sulfate (SGFSLS). These media induced better solubility of low soluble compounds but on the 
other hand they were not physiologically relevant [7]. 
Although the composition of artificial fluids reflects specific parameters of GIT physiology, they are not 
adequate models of in vivo conditions [2]. Thus, Fasted State Simulated Gastric Fluid (FaSSGF) and Fasted 
State Simulated Intestinal Fluid (FaSSIF) have been regarded as biorelevant media. FaSSGF was proposed by 
Vertzoni et al. in 2005 [8] and FaSSIF by Galia at al. in 1998 [4]. Both biorelevant media contain natural 
surfactants: taurocholate sodium, which represents bile salts, and lecithin. The medium FaSSGF comprises 
the enzyme pepsin as the medium SGF but pepsin is contained in very low concentration in FaSSGF. Unlike 
SIF, FaSSIF does not comprise the enzyme pancreatin.  
All reported media were developed for the simulation of fasting conditions in the upper GIT. Media 
simulating fed state of stomach (Fed State Simulated Gastric Fluid, FeSSGF) and small intestine (Fed State 
Simulated Intestine Fluid, FeSSIF) have been also developed. Former researches about the simulation of 
postprandial gastric conditions tested homogenized breakfasts with milk and nutrition products [2]. The 
first proposal of FeSSIF was published by Galia at al. in 1998 [4]. Updates media (snapshot media) were 
proposed by Jantratid et al. in 2008 [9]. However, this study is not interested in fed state media since their 
composition hinders direct spectrophotometric analysis. 
The biorelevant dissolution properties of many drugs have been studied since the beginning of 
biorelevant media development. Studies of solubility in biorelevant media were carried out to predict 
bioavailability particularly of ionisable molecules since the solubility of ionisable compounds depends on 
their pKa and pH of the media [10]. The solubilizing effect of bile salts, lecithin and other food effects on 
drug solubilization were tested for instance by Takács-Novák et al. [10], Frank et al. [11], Dressman at al. 
[12], and Kostewicz et al. [13]. 
 
Figure 1. Structure of candesartan cilexetil (CC) 
The precise imitation of the in vivo conditions is desirable particularly for poorly soluble drugs. As a case 
example of poorly soluble drug candesartan cilexetil (Figure 1) was chosen which is practically insoluble in 
water (less than 0.05 µg/ml [14]). As prodrug, candesartan cilexetil (CC) is completely bioactivated by ester 
hydrolysis to candesartan during a gastrointestinal absorption. Actually, candesartan is an angiotensin II 
receptor antagonist and it is mainly indicated for the treatment of hypertension [15]. However, CC is 
classified as BCS Class II drug and its very low solubility across the physiological pH range brings about an 
incomplete absorption and it is a reason for low bioavailability (about of 15 % [14]). The compound of our 
interest is a weak acid (pKa 6.0 [16]) with lower solubility in low pHs due to deprotonation of a tetrazole 
group at pHs higher than 6 [16]. The results from our study confirm an increase in CC solubility with 
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increasing pH. Moreover, the solubility of CC is enhanced using surfactant Tween 20 and the surfactant is 
required to achieve sink conditions. The dissolution testing of CC for quality controls has been standardly 
carried out in 900 ml of 0.05 M phosphate buffer (pH 6.5) with 0.35 % or 0.7 0% (w/w) Tween 20 (shortcut 
PPT20). The amount of Tween 20 depends on dosing conditions [17]. 
A big challenge with CC is its low stability in solutions. The most important factors affecting the stability 
of CC in solution are pH and temperature. Hoppe and Sznitowska [18] found out that the degradation rate 
of CC was faster at elevated temperatures and low pHs. According to their results, the half-life of 
degradation is only 35.91 hours in 0.1 M HCl (pH 1.2) and 150.7 hours in 0.05 M phosphate buffer (pH 6.5), 
both at 37 °C and without surfactants [18]. 
Our aim was to study and compare the dissolution properties of CC in media simulating the fasted state 
of stomach and small intestine. This paper provides the solubility data and dissolution profiles of CC in 
various media (artificial media with or without surfactant and enzyme, biorelevant media) which will be 
helpful for prediction of the in vivo performance of CC after oral administration. 
Experimental 
Materials 
Candesartan cilexetil and immediate release (IR) tablets Carzap (product of Zentiva k.s., Czech Republic) 
with 8 mg of CC were obtained as gift samples. All chemicals used in the study were of analytical grade. The 
composition of the prepared media is presented in Table 1 and Table 2. 
 
Table 1. Composition of gastric media. 
Component FaSSGF SGF SGFsp SGFSLS SGFTriton 
Sodium taurocholate (mM) 0.08 - - - - 
Lecithin (mM) 0.02 - - - - 
Sodium lauryl sulfate (%, w/v) - - - 0.25 - 
Triton X-100 (%, w/v) - - - - 0.10 
Pepsin (mg/ml) 0.10 3.20 - - - 
Sodium chloride (mM) 34.20 34.20 34.20 34.20 34.20 
pH (adjusted by hydrochloric acid) 1.6 1.2 1.2 1.2 1.2 
 
Table 2. Composition of intestinal media. 
Component FaSSIF SIFsp PPT20 
Sodium taurocholate (mM) 3.00 - - 
Lecithin (mM) 0.75 - - 
Tween 20 (%, w/w) - - 0.35 
Pancreatin (mg/ml) - - - 
Monobasic sodium phosphate (mM) 28.36 - - 
Monobasic potassium phosphate (mM) - 49.97 50.00 
Sodium hydroxide (mM) 8.70 45.00 - 
Sodium chloride (mM) 105.85 - - 
pH (adjusted by sodium hydroxide) 6.5 6.8 6.5 
 
 




The solubility of CC was determined by the shake-flask method. CC was added in excess into specific 
solvent and shaken for 24 hours at 37 °C in a thermostated orbital platform shaker (Heidoplh, Unimax 1010 
with Incubator 1000) to obtain equilibrium solubility [18, 19]. Due to the low stability of CC, a ‘shortened 
shake flask method’ was suggest, the shaken time of certain saturated solutions, namely with solvents SGF, 
FaSSGF and SGFTriton, was only 2 hours or 12 hours. The concentration of CC was measured by a UV-Vis 
spectrophotometer (Schimadzu UV Mini 1240) at 256 nm and before the analysis supernatant had been 
filtered through a 35 micron porous filter from UHMW polyethylene. All tests were carried out in triplicate. 
Concentration of dissolved CC was determined from calibration curve. The stock solution of CC was 
prepared in the suitable quantity of methanol. The aliquot of this solution was diluted with the specific 





Dissolution tests were performed in a paddle apparatus (USP II). The stirring rate was 50 rpm. The 
dissolution medium was filtered through a 35 micron porous filter from UHMW polyethylene, pumped 
through a 10 mm flow cell by a peristaltic pump (Ismatic, Reglo Digital MS-2/6) and analyzed by a UV-Vis 
spectrophotometer (Schimadzu UV Mini 1240), wavelenght was 256 nm. All dissolution tests were 
conducted in triplicate. The tablets of CC were placed in 500 ml of dissolution medium (37±0.5 °C). The 
volume was set as the smallest amount which enables the performance of the dissolution testing in USP II 
[2]. To simulate the fasted state, the volume of media in the range of 250-300 ml (stomach) or 300-500 ml 
(duodenum) is recommended [8], but the volume reduction was not feasible. Despite the volume 
reduction, sink conditions were maintained in medium PPT20 regarding on our solubility data of CC. These 
data verify findings reported by Hoppe and Sznitowska [18]. 
Results and Discussion 
Solubility study 
The equilibrium solubility data (Table 3) confirm that CC is a poorly soluble and stable compound. The 
values of CC solubility in SGF after 24 hours of shaking were so small that it was not possible to record 
them by the UV-Vis spectrophotometer. Zero solubility in SGF and very low solubility in FaSSGF 
(0.72±0.19 µg/ml) were caused by the rapid CC degradation at the acid environment. Due to the long 
measurement time, the large amount of CC degraded. Because of the CC degradation, the shaking time 
was shortened to two hours for media SGF, FaSSGF and SGFTriton. From the obtained data, we concluded 
that the shorter shaking time reduced the amount of emerging degradation products (CC saturation 
solubility was 2.76 µg/ml in SGF and 0.90 µg/ml in FaSSGF). But the equilibrium may not be always reached 
in such short time, as evidenced by almost ten times lower value of CC solubility in SGFTriton (0.69 µg/ml 
after 2 hours compared to 6.00 µg/ml after 24 hours test). CC gained the greatest solubility in FaSSGF after 
12-hour period of shaking (1.59 µg/ml). For these data, it can be concluded that 12 hours is an optimal 
period for the shake-flask method considering the solubility and degradation of CC in FaSSGF. 
Very low amounts of CC were dissolved in SGFsp and SIFsp, 1.35 and 0.65 µg/ml, respectively. In this case, 
the low solubility of CC was probably the main reason of such results. We observed that the powder of CC 
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was almost dry after the tests because in the media without enzymes and surfactants the required wetting 
of the samples was not reached. Satturwar et al. published the values of CC solubility in SGF (0.6 µg/ml) 
and SIF (8.6 µg/ml) [20]. However, the preparations of these media and the conditions of solubility study 
were not described in the research paper. Besides, we suppose that the used media did not contain 
enzymes, which means SGFsp and SIFsp, due to other procedures mentioned in the paper. Our solubility data 
of CC measured by a shake-flask method in SGFsp and SIFsp do not correspond with data by Satturwar et al. 
[20]. Our CC solubility in SGFsp is twice as high and CC solubility in SIFsp 13 times as low than Satturwar’s 
data. 
Table 3. Saturation solubility of CC in used media. 
Medium 
Solubility of CC (µg/ml) 
Shortened test Standard test (24-hour) 





SGF 2.76±0.46* - 
SGFsp - 1.35±0.10 
SGFTriton 0.69±0.07* 6.00±0.25 
SGFSLS - 147.63±0.35 
SIFsp - 0.65±0.01 
FaSSIF - 8.26±0.18 
*  2-hour test 
**12-hour test 
Results demonstrate that only in the media SGFSLS (147.63 µg/ml) and PPT20 (93.00 µg/ml) sink 
conditions for 8 mg tablets of CC can be achieved in volume 500 ml. Three liters of FaSSIF and four liters of 
SGFTriton were required to achieve minimum sink conditions (approximately 30 % of the saturation 
concentration of CC) in dissolution studies. However, so large volumes are not physiologically relevant. 
Based on solubility studies, it is expected that in the biorelevant media for fasted state conditions are not 
sufficient to achieve complete dissolution of the minimum dose. 
Dissolution study 
The dissolution properties of CC are influenced by pH due to the ionization effect of CC at pHs above 
6.0, and also by the presence of a surfactant. The similar amount of CC (12-13 %) was dissolved in SGF and 
FaSSGF media (Figure 2) at pH 1.2 and 1.6, respectively. It was predictable from the results of saturation 
solubility. Dissolution testing proved the same dissolution rate of CC. Very small divergence between 
profiles of SGF and FaSSGF is caused by the close values of pH and the low concentration level of the 
natural surfactants in FaSSGF. Despite the fast degradation of CC at acid pH, the decrease of the CC 
concentration was not observed during one hour. However, 5 % decrease of the CC concentration was 
observed throughout the dissolution tests in SGFsp (Figure 3). Less considerable, but still noticeable, 0.5% 
reduction occurred also in case of the dissolution CC in SIFsp. These courses of the dissolution profiles in 
SGFsp and SIFsp prove the extremely short-time stability of CC in aqueous environment without surfactants 
or enzymes. The reason why the medium SIFsp instead of SIF was used is that pancreatin coloured the 
medium and SIF could not be analyzed by a spectrophotometric technique. The amounts of dissolved CC in 
35 minutes in SGF (12 %) and SIFsp (10 %) were close to each other until the degradation process in SIFsp 
occured. Similar dissolution profiles were achieved in spite of the low pH value in SGF (SGF-pH 1.2 and 
SIFsp-pH 6.8, the highest pH of the used media) on the one hand and the low equilibrium solubility of CC in 
SIFsp on the other hand. Nevertheless, the ionization of CC molecules at pHs above 6.0 probably occurred 
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during the dissolution test. The ionization resulted in solubility increase and subsequently the degradation 
of dissolved compound. 
 
 
Figure 2. Dissolution profiles of candesartan cilexetil in medium PPT20, FaSSGF, SGF, SGFTriton, SGFSLS and 
FaSSIF  
The most promising medium for the dissolution testing of CC was considered FaSSIF, the medium with 
pH 6.5 and the natural surfactants taurocholate sodium and lecithin. However, the CC solubility in this 
medium was not sufficient. For this reason, sink conditions were not obtained in the paddle apparatus and 
therefore, the dissolution rate and extent of the CC solubility (46 %) was reduced (Figure 2). 
 
Figure 3. Dissolution profiles of candesartan cilexetil in medium SGF, SGFsp and SIFsp 
The biorelevant dissolution profiles of CC are not accordant with the dissolution profiles of CC in the 
media with the artificial surfactants, especially with the surfactant Tween 20 and sodium lauryl sulfate 
(Figure 2). It was found for CC that solubilization plays much more determining role in solubility than 
ionization. The solubility and dissolution rate of CC in the media PPT20 (96 %) and SGFSLS (72 %) are 
considerately higher. In the case of SGFSLS it is despite the low pH value (pH 1.2). The increase of the 
solubility in the medium containing the surfactant Triton X®-100 is not so pronounced (31 %). This indicates 
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how the choice of a surfactant influences the resulting solubility of a drug. It is evident that the application 
of dissolution media with artificial surfactants would lead to false positive results because artificial 
surfactants induce greater solubilization effects than what would be physiologically relevant. 
Conclusions 
The need for in vitro test which mimics in vivo conditions of the gastrointestinal tract led to the 
development of physiologically relevant dissolution media. The dissolution of the poorly soluble drug CC 
was studied in different type of dissolution media: the compendial medium (PPT20) commonly used for 
quality control, the artificial fluids with the synthetic surfactants (SGFTriton, SGFSLS) or without them (SGF, 
SGFsp, SIFsp) and the fasted state simulating biorelevant media (FaSSGF, FaSSIF). In this study, the 
dissolution media that are possible to analyse by a UV-Vis spectrophotometer were examined. 
Consequently, dissolution tests with medium SIF and biorelevant media simulated fed state (FeSSGF and 
FeSSIF) were not carried out. 
The amount of dissolved CC in the biorelevant media was significantly lower than the amount of CC 
dissolved during tests with the media containing the synthetic surfactants. Whereas the biorelevant media 
contain natural surfactants as an alternative to the non-physiologically relevant surfactants, the dissolution 
profiles of CC corresponded with the in vivo behavior of CC closely in FaSSGF and FaSSIF. The poor solubility 
and stability of CC in the biorelevant media resulted in its low bioavailability. The results can be utilized as 
an example that the biorelevant media are useful to forecast the oral absorption of a BCS Class II drug. 
List of abbreviations 
CC candesartan cilexetil 
FaSSGF fasted state simulated gastric fluid 
FaSSIF fasted state simulated intestinal fluid 
FeSSGF fed state simulated gastric fluid 
FeSSIF fed state simulated intestinal fluid 
GIT gastrointestinal tract 
PPT20 phosphate buffer with surfactant Tween 20 
SGF simulated gastric fluid 
SGFsp simulated gastric fluid sine pepsin 
SGFSLS simulated gastric fluid without enzyme but with surfactant sodium lauryl sulfate 
SGFTritin simulated gastric fluid without enzyme but with surfactant TritonX® 100 
SIF simulated intestinal fluid 
SIFsp simulated intestinal fluid sine pancreatin 
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